Sheet 1 of 3Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17118-056002/2835BApplication No.
10/762,226**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Gevas et al.Filing Date
January 20, 2004Group Art Unit
1642**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0058040	05/16/02	Grimes et al.			
	AB	2002/0095028	7/18/2002	Grimes et al.			
	AC	2003/0021786	1/30/2003	Gevas et al.			
	AD	2003/0068326	4/10/2003	Gevas et al.			
	AE	2003/0086941	5/8/2003	Michaeli et al.			
	AF	2003/0091574	5/15/2003	Gevas et al.			
	AG	2004/0001842	1/1/2004	Michaeli et al.			
	AH	2005/0069966	3/31/2005	Grimes et al.			
	AI	2005/0187152	8/25/2005	Gevas et al.			
	AJ	2006/0020119	1/26/2006	Grimes et al.			
	AK	2006/0039911	2/23/2006	Gevas et al.			
	AL	2006/0140962	6/29/2006	Gevas et al.			
	AM	5,688,506	11/18/97	Grimes et al.			
	AN	6,169,173	01/02/01	Wank			
	AO	6,191,290	02/20/01	Safavy			
	AP	6,303,123	10/16/01	Grimes et al.			
	AQ	6,359,114	3/19/2002	Grimes et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AR	90/08774	08/09/90	PCT				
	AS	95/13297	05/18/95	PCT				
	AT	98/51337	11/19/98	PCT				
	AU	99/59612	11/25/99	PCT				
	AV	99/59628	11/25/99	PCT				
	AW	02/076499	10/03/02	PCT				

Examiner Signature


Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date January 20, 2004	Group Art Unit 1642

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
S	AX	Aphthon Biopharma <i>BIO2005 Presentation</i> , June 19-22, Philadelphia, PA (2005), 26 pages
	AY	Baba <i>et al.</i> , "Glycine-extended gastrin induces matrix metalloproteinase-1- and 3-mediated invasion of human colon cancer cells through type I collagen gel and Matrigel" <i>Int. J. Cancer</i> 111(1):23-31 (2004)
	AZ	Berd <i>et al.</i> , "Induction of Cell-mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with a Melanoma Cell Vaccine Preceded by Cyclophosphamide," <i>Cancer Res.</i> 46:2572-2577 (1986)
	BA	Buchan <i>et al.</i> , "Regulatory peptides in Barrett's oesophagus," <i>J. Pathol.</i> 146(3):227-234 (1985)
	BB	Caplin <i>et al.</i> , "Expression and processing of gastrin in hepatocellular carcinoma, fibromellar carcinoma and cholangiocarcinoma," <i>J. Hepatology</i> 30(3):519-526 (1999)
	BC	Caplin <i>et al.</i> , "Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines" <i>Digestive Diseases and Sciences</i> 46(7):1356-1366 (2001)
	BD	Caplin <i>et al.</i> , "Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy" <i>Regulatory Peptides</i> 84(1-3):81-89 (1999)
	BE	Clerc <i>et al.</i> , "Differential Expression of the CCK-A and CCK-B/Gastrin Receptor Genes in Human Cancers of the Esophagus, Stomach, and Colon," <i>Int. J. Cancer</i> 72:931-936 (1997)
	BF	"Gastrin 17 vaccine-Aphthon: Anti-gastrin 17 immunogen, G17DT," <i>Biodrugs</i> 17(3):223-225 (2003)
	BG	Gocyk <i>et al.</i> , "Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer," <i>Med. Sci. Monit.</i> 6(6):1085-1092 (2000)
	BH	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> , 278(5340):1041-1042 (1997)
	BI	Harris <i>et al.</i> , "An Antiapoptotic Role for Gastrin and the Gastrin/CCK-2 Receptor in Barrett's Esophagus," <i>Cancer Res.</i> 64:1915-1919 (2004)
	BJ	Jain, R.K., "Barriers to drug delivery in solid tumors," <i>Sci. Am.</i> 171(1):58-65 (1994)
	BK	Kelley <i>et al.</i> , "Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer," <i>Chest</i> , 112:256-261 (1997)
	BL	Koh <i>et al.</i> , "Glycine-Extended Gastrin Promotes the Growth of Lung Cancer," <i>Cancer Res.</i> 64:196-201 (2004)
	BM	McWilliams <i>et al.</i> , "Antibodies raised against the extracellular tail of the CCKB/gastrin receptor inhibit gastrin-stimulated signaling," <i>Regulatory Peptides</i> 99(2-3):157-161 (2001)
	BN	MSNBC News Services, "Mixed results on new cancer drug," November 9, 2000 (4 pages)
	BO	Moody <i>et al.</i> , "GRP Receptors Are Present in Non Small Cell Lung Cancer Cells," <i>J. Cell Biochem. Suppl.</i> , 24:247-256 (1996)
	BP	Mulholland <i>et al.</i> , "Elevated Gastric Acid Secretion in Patients with Barrett's Metaplastic Epithelium," <i>Dig Dis. Sci.</i> 34(9):1329-1334 (1989)
	BQ	Osband, M.E. and S. Ross, "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Immunology Today</i> , 11:193-195 (1990)
	BR	Pannequin <i>et al.</i> , "Divergent roles for ferric ions in the biological activity of amidated and non-amidated gastrins," <i>J. Endocrinol.</i> 181(2):315-325

Examiner Signature 	Date Considered 1/20/06
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date January 20, 2004	Group Art Unit 1642

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
Su	BS	Rehfeld, J.F., "Three components of gastrin in human serum," <i>Biochim. Biophys. Acta.</i> , 285:364-372 (1972)
	BT	Smith <i>et al.</i> , "Gastrin and colorectal cancer," <i>Alimentary Pharmacology & Therapeutics</i> 14:1231-1247 (2000)
	BU	Smith <i>et al.</i> , "Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence," <i>Gut</i> 47(6):820-824 (2000)
	BV	Smith <i>et al.</i> , "Gastrin may have an autocrine/paracrine role in Barrett's oesophagus and oesophageal adenocarcinoma," <i>Br. J. Surgery</i> 84:706-707 (1996).
	BW	Smith <i>et al.</i> , "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer," <i>Clin. Cancer Res.</i> 6(12):4719-4724 (2000)
	BX	Thorndyke, M. and G.J. Dockray, "Identification and localization of material with gastrin-like immunoreactivity in the neutral ganglion of a photochordate, <i>Ciona intestinalis</i> ," <i>Regulatory Peptides</i> 16:269-279 (1986)
	BY	Torosian <i>et al.</i> , "Colon carcinoma metastatic to thigh - an unusual site of metastasis. Report of a case," <i>Diseases of the Colon and Rectum</i> 30(10):805-808 (1987)
	BZ	Watson <i>et al.</i> , "Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumor cells," <i>Cancer</i> 68(6):1255-1260 (1991)
	CA	Watson <i>et al.</i> , "Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model," <i>Int. J. Cancer</i> 75(6):873-877 (1998)
	CB	Watson <i>et al.</i> , "Expression of gastrin/CCKB receptor isoforms in gastrointestinal tumor cells: Relationship to gastrin secretion," <i>Scientific Proceedings of the 88th Annual Meeting of the American Association for Cancer Research</i> , April 12-16, 1997, San Diego, California, Volume 38(0):116 (Abst. # 773) (1997)
	CC	Watson <i>et al.</i> , "Antiserum raised against an Epitope of the Cholecystokinin B/gastrin receptor Inhibits Hepatic Invasion of a Human Colon Tumor," <i>Cancer Res.</i> 60(20):5902-5907 (2000)
	CD	Watson <i>et al.</i> , "Gastrin antagonists and gastrointestinal tumors," <i>Expert. Opin. Invest. Drugs</i> 4(12):1253-1266 (1995)
	CE	Watson <i>et al.</i> , "Antibodies Raised by Gastrimmune Inhibit the Spontaneous Metastasis of a Human Colorectal Tumour, AP5LV," <i>European J. Cancer</i> 35(8):1286-1291 (1999)
	CF	Watson <i>et al.</i> , "A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice," <i>Int. J. Cancer</i> 81(2):248-254 (1999)
	CG	Watson <i>et al.</i> , "G17DT-A new weapon in the therapeutic armoury for gastrointestinal malignancy," <i>Expert Opin. Biol. Ther.</i> 1(2):309-317 (2001)
	CH	Watson <i>et al.</i> , "Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide," <i>Eur. J. Cancer</i> 28A(8-9):1462-1467 (1992)
	CI	Watson <i>et al.</i> , "The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin," <i>Int. J. Cancer</i> 43:692-696 (1989)
	CJ	Watson <i>et al.</i> , "Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth," <i>British Journal of Cancer</i> 65(6):879-883 (1992)
	CK	Weiner, L.M., "An Overview of Monoclonal Antibody Therapy of Cancer," <i>Seminars in Oncology</i> 26(4)(Supp. 12):41-50 (1999)

Examiner Signature 	Date Considered 12/20/06
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	